Hemocompatibility and cytotoxicity of small-diameter bioabsorbable tissue-engineered vascular grafts depending on anti-thrombogenic and antimicrobial coating

Eugenia O. Krivkina, Elena A. Velikanova, Eugenia A. Senokosova, Maryam Yu. Khanova, Tatyana V. Glushkova, Larisa V. Antonova, Leonid S. Barbarash

Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia

Received 1 October 2021, Revised 26 November 2021, Accepted 10 December 2021

Abstract: Anti-thrombogenic and antimicrobial coatings of polymer grafts constitute a promising approach to preventing infection and thrombosis of vascular grafts. The objective was to study the hemocompatibility and cytotoxicity of PHBV/PCL grafts with iloprost and amphiphilic coating. Material and Methods — Polymer matrices were manufactured by electrospinning a mixture of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) and poly(e-caprolactone) (PCL) polymers. Several matrices were modified by complexation between polyvinylpyrrolidone (PVP) and cationic amphiphile and/or iloprost. The amphiphile was covalently cross-linked to the surface of other PHBV/PCL matrices. Unmodified PHBV/PCL matrices were used as the control group. Hemocompatibility and cytotoxicity of scaffolds before and after the modification were evaluated. Results — The hemocompatibility assessment revealed that hemolysis degree did not exceed normal values in all types of matrices. The PHBV/PCL/PVP matrices had increased platelet aggregation on the surface of the grafts. Subsequent addition of iloprost and amphiphile resulted in a sevenfold reduction of platelet aggregation. In PHBV/PCL/PVP matrices, the degree of platelet adhesion increased without changing the platelet deformation index values. Iloprost and amphiphilic coating of PHBV/PCL/PVP matrices diminished the number of adhered platelets and platelet deformation index by 1.5 times. The amphiphile, covalently cross-linked to PHBV/PCL matrices, caused a negative effect on the platelet adhesion, aggregation, and deformation index values. Evaluation of cytotoxicity of PHBV/PCL/PVP matrices, coated with iloprost and/or cationic amphiphile, demonstrated a slight decline in the rates of cell growth and proliferation after three days. Moreover, after three days, cell deaths and a sharp drop in the cell index values were noted in PHBV/PCL matrices with covalently cross-linked amphiphile. Conclusion — Iloprost and amphiphilic coating of PHBV/PCL grafts has increased their hemocompatibility. Also, there were no signs of cytotoxicity while using the complexation technique. However, covalently cross-linked amphiphile caused an increase in the cytotoxicity of matrices, which may have been indicative of the negative effect observed in this type of surface modification.

Keywords: vascular prostheses, hemocompatibility, electrospinning, cationic amphiphiles, cytotoxicity.

Cite as Krivkina EO, Velikanova EA, Senokosova EA, Khanova MYu, Glushkova TV, Antonova LV, Barbarash LS. Hemocompatibility and cytotoxicity of small-diameter bioabsorbable tissue-engineered vascular grafts depending on anti-thrombogenic and antimicrobial coating. Russian Open Medical Journal 2021; 10: e0423.

Introduction

Tissue engineering is among the most promising fields of vascular graft research that has the potential to create a vascular graft with a tubular matrix made of natural and/or synthetic bioabsorbable and biocompatible polymers. Such matrix is a scaffold that can be subsequently populated by autologous cells in vitro or in situ [1]. Despite widespread use of polymer grafts in cardiovascular surgery, the graft infection remains a serious problematic issue with severe complications and high mortality rates [2]. It is difficult to establish specific etiology of graft infections, since they are usually multifactorial [3]. Bacteria may originate from an exogenous or endogenous source (bacteremia) [4, 5]. Despite the sterile conditions in the course of implantation, about 20% of grafts become infected, increasing the percentage of subsequent occlusion to 27% [6]. Pathogenic bacteria are able to colonize the graft surface, forming a protective biofilm that increases their antibiotic resistance and host defense mechanisms, which may lead to a vascular graft replacement [7, 8]. The biofilm formation could be prevented by replacing the usual graft materials with antimicrobial and biocompatible polymers, or by an additional antimicrobial treatment [9, 10]. Taking into account the declining
effectiveness of antibacterial medicines due to the emergence of bacteria with multiple drug resistance, the development of vascular grafts with antimicrobial coatings that have a low chance of inducing antibiotic resistance becomes very relevant. Immobilizing the antibacterial preparation directly on the surface of the grafting would solve the problem of local drug delivery, and ensure the proper effect on microorganisms prior to the biofilm formation.

In the last decade, hydrogels have become widespread in cardiovascular surgery due to their ability to deliver pharmaceutical drugs and release them over long periods of time [11]. Hydrogels are represented by the three-dimensional polymer networks obtained from water-soluble or bioabsorbable natural/synthetic polymers with antibacterial agent bound to the polymer matrix by non-covalent interactions.

Cationic amphiphiles are single or multiple positively charged molecules with lipophilic fragments which can potentially resolve the problem of drug resistance and help creating an effective antimicrobial coating [12, 13]. These compounds are synthetic analogs of natural cationic antimicrobial peptides. They can cause disruption of the transmembrane potential, cytoplasmic content leakage, and, ultimately, cell death [12]. Most of these compounds are highly effective against both gram-positive and gram-negative bacteria (including multidrug-resistant bacteria). The amphiphiles that destroy bacterial membranes and, simultaneously, other targets, can significantly reduce the likelihood of bacteria developing resistance to such compounds. High stability of these compounds, even in physiological fluids, in combination with their low cost, makes them the most promising candidates for the role of low molecular weight modifiers of polymer materials.

An important issue in manufacturing the tissue-engineered vascular grafts is ensuring the porosity of the graft wall, since it is required to provide full migration of cells from the bloodstream and surrounding tissues, cell proliferation, and differentiation. However, such porous surface could lead to the thrombus formation. Consequently, additional modification to the surface of grafts with antiplatelet and anticoagulant agents could prevent the thrombus formation after graft implantation.

Moreover, it is also necessary to take into account the cytotoxicity of drugs and binding agents used for antimicrobial and anti-thrombogenic coatings in the course of the manufacturing process.

Material and Methods

Manufacturing the vascular grafts

Small-diameter vascular grafts (4 mm) were produced by emulsion electrospinning a mixture of 2% poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV, Sigma-Aldrich, USA) and 12% poly(ε-caprolactone) (PCL, Sigma-Aldrich, USA); 1,1,1,3,3,3-hexafluoro-2-propanol (Sigma-Aldrich, USA) was used as a solvent. Electrospinning was performed using a Nanon-01A nanofiber electrospinning system (MECC, Inc., Japan) at a voltage of 20 kV, a solution feed rate of 0.5 mL/h, a collector rotation speed of 1000 rpm, a needle movement speed of 60 mm/s, and 150 mm distance from the needle to the collector.

Anti-thrombogenic and antimicrobial coatings of vascular grafts

Surface modification of the manufactured polymer scaffolds was performed in two different ways: some of the manufactured vascular grafts were modified sensu our own original technique of forming a polyvinylpyrrolidone (PVP) hydrogel coating on the inner surface. To achieve this, the grafts were placed in argon-filled glass test tubes, then sealed with parafilm and irradiated at a dosage of 15 kGy using an ILU-10 accelerator with energy range up to 5 MeV and beam power of 50 kW (Budker Institute of Nuclear Physics at the Siberian Branch of Russian Academy of Sciences). Hence, sterilization of vascular grafts took place along with their modification. Consequently, all further manipulations were carried out under sterile conditions. Then, platelet antiaggregant, iloprost (Ilo), and/or cationic amphiphile, 1,5-bis-(4-tetradecyl-1,4-diazoniabicyclo[2.2.2]octan-1-yl) pentane tetrabromide (A), with antimicrobial and antiviral properties were added to the PVP hydrogel coating via employing the complexation technique [14].

All other grafts were modified by covalent crosslinking, implemented via immobilization of the amphiphile on the surface of nonwoven matrix due to activation of carboxyl groups in the polymer by a water-soluble carbodiimide, followed by the treatment with a peptide solution.

Hemocompatibility analysis

Hemocompatibility of grafts was assessed via hemolysis analysis and platelet adhesion, aggregation, and deformation index.

Hemolysis

The assessment of the hemolysis degree after the contact with the surface of polymer samples was conducted sensu the ISO 10993.4 standards: 3.8% sodium citrate was added to the fresh donor blood in the ratio of 1:9. Five samples of 25 cm² each were placed in weighing cups containing 10 mL of physiological solution, and were incubated for 120 min at 37 °C. Saline and distilled water were used as positive and negative controls, respectively. After two hours of incubation, 200 µL of citrated blood was added to each cup for further incubation during 60 min at 37 °C. Then, the polymer samples were transferred from the cups into test tubes and centrifuged for 10 min at 2,800 rpm to precipitate the remaining cells. Optical density of obtained supernatants was measured using the GENESYS 6 spectrophotometer (Thermo Scientific, USA) at a wavelength of 545 nm.

The percentage of hemolysis (H) was calculated via the following equation [15, 16]:

\[ H(\%) = \frac{D_{p} - D_{p0}}{D_{p0}} \times 100\% \]

where, \( D_{p} \) is the optical density of incubated sample; \( D_{p0} \) is the optical density of the positive control; \( D_{p0} \) is the optical density of the sample with 100% hemolysis.

Zero hemolysis value was defined as the mean optical density of saline-diluted blood (positive control); 100% hemolysis value was defined as the mean optical density of blood diluted with distilled water: \( D_{p0}=0.279 \) (negative control).

Platelet aggregation

The study was carried out in accordance with the ISO 10993.4 standard procedures. To obtain platelet-rich plasma (PRP), citrated blood was centrifuged for 10 min at 1,000 rpm. Platelet-poor plasma (PPP) was obtained by repeated centrifugation of PRP for...
20 min at 4,000 rpm. The centrifuge was properly calibrated. Intact PRP was used as a positive control. The measurements were performed in a spontaneous mode without aggregation inducers. CaCl₂ (0.025 mol/L) was used to restore the level of Ca²⁺ in citrated blood. The reagent mixture contained 250 µL of PRP and 25 µL of CaCl₂. The contact time of the test samples with PRP was 3 min, after which the measurements were made. The platelet maximum aggregation rate was measured by the semi-automated 4-channel platelet aggregometer APACT 4004 (LABiTec, Germany).

**Platelet adhesion and platelet deformation index**

Samples of polymer matrices (n=5), 0.5 cm² each, were incubated with fresh citrated donor blood by centrifugation for 10 min at 1,200 rpm. Next, test samples were rinsed with phosphate-buffered saline (PBS, pH 7.4) in order to remove non-adherent plasma components. Then the samples were fixed in a 2% glutaraldehyde solution for 24 hours, rinsed with PBS and dehydrated in alcohols with concentrations ranging from 30% to 100% for 15 minutes each, followed by drying at a room temperature. Later on, samples were mounted on special tables by means of the carbon tape to form a conductive (Au/Pd) coating, using EM ACE200 vacuum coater (Leica Mikrosysteme GmbH, Austria). For analysis, we randomly selected 8 samples. The adhesion ability of their surfaces was assessed with means of the platelet count (platelet per 1 mm²), predominant platelet type on the surface, and also by platelet deformation index (PDI), calculated by the following formula [15-18]:

\[
PDI = \frac{\text{number of type I platelets} \times 1 + \text{number of type II platelets} \times 2 + \text{number of type III platelets} \times 3 + \text{number of type IV platelets} \times 4 + \text{number of type V platelets} \times 5}{\text{total number of platelets}}.
\]

![Figure 1. Surfaces of PHBV/PCL matrices after the contact with PRP (×2000 magnification).](image)

| Sample type | PHBV/PCL | Unmodified matrix | PHBV/PCL/PVP | Matrix polymerized with polyvinylpyrrolidone | PHBV/PCL/PVP/Ilo/A | Matrix modified by complexation between polyvinylpyrrolidone and iloprost and amphiphile coating | PHBV/PCL/A | Matrix polymerized with polyvinylpyrrolidone and iloprost | PHBV/PCL/A/Ilo/A | Matrix with covalently cross-linked cationic amphiphile |
|-------------|----------|------------------|--------------|---------------------------------------------|--------------------|-------------------------------------------------|------------|--------------------------------------------------|------------------|---------------------------------------------------|

**Table 1. Types of manufactured polymer samples used to evaluate hemocompatibility**

| Sample type | PHBV/PCL | Unmodified matrix | PHBV/PCL/PVP | Matrix polymerized with polyvinylpyrrolidone | PHBV/PCL/PVP/Ilo/A | Matrix modified by complexation between polyvinylpyrrolidone and iloprost and amphiphile coating | PHBV/PCL/A | Matrix polymerized with polyvinylpyrrolidone and iloprost | PHBV/PCL/A/Ilo/A | Matrix with covalently cross-linked cationic amphiphile |
|-------------|----------|------------------|--------------|---------------------------------------------|--------------------|-------------------------------------------------|------------|--------------------------------------------------|------------------|---------------------------------------------------|

**Table 2. The degree of hemolysis and maximum aggregation in human blood platelets after their contact with modified and unmodified polymer matrices**

| Sample type | Maximum platelet aggregation, % Me (25%-75%) | The degree of hemolysis, % Me (25%-75%) |
|-------------|---------------------------------------------|------------------------------------------|
| PHBV/PCL    | 87.23 (83.95-89.84) *                        | 0.504 (0.0-1.01)                          |
| PHBV/PCL/PVP| 88.53 (86.59-89.37) *                        | 0.2 (0.0-0.5)                             |
| PHBV/PCL/PVP/Ilo/A | 12.18 (11.15-12.24) * | 0.5 (0.0-0.5) |
| PHBV/PCL/A  | 83.28 (83.21-84.86)                          | 100 (100-100)                            |
| Intact platelet-rich plasma (PRP) | 74.65 (72.45-75.31) | -- |

* p<0.05 relative to intact PRP; # p<0.05 relative to unmodified PHBV/PCL matrices.

**Table 3. Platelet adhesion indicators after the contact with PHBV/PCL polymer matrices, depending on the coating type**

| Sample type | Platelet type, % | Platelet count per mm² Me (25%-75%) | Platelet deformation index Me (25%-75%) |
|-------------|------------------|-------------------------------------|------------------------------------------|
| PHBV/PCL    |                  | 578.0 (0.0-1439.0)                  | 1.75 (0.0-2.9)                           |
| PHBV/PCL/PVP|                  | 1156.0 (0.0-3082.0)                 | 1.91 (0.0-2.9)                           |
| PHBV/PCL/PVP/Ilo/A |              | 770.6 (0.0-1445.0)                 | 1.3 (0.0-2.4)                            |
| PHBV/PCL/A  |                  |                                    |                                          |

* p<0.05 relative to the values of the PHBV/PCL matrix indicators; # p<0.05 to the values of the PHBV/PCL/PVP indicators.

**Table 4. Types of polymer samples used for cytotoxicity analysis**

| Sample type | PHBV/PCL | Unmodified matrix | PHBV/PCL/PVP/Ilo/A | Matrix polymerized with polyvinylpyrrolidone and iloprost | PHBV/PCL/PVP/A | Matrix polymerized with polyvinylpyrrolidone and amphiphile | PHBV/PCL/PVP/Ilo/A | Matrix polymerized with polyvinylpyrrolidone and iloprost with amphiphile | PHBV/PCL/A | Matrix with covalently cross-linked cationic amphiphile |
|-------------|----------|------------------|--------------------|----------------------------------------------------------|---------------|-----------------------------------------------------------|--------------------|---------------------------------------------------------|------------|--------------------------------------------------------|

© 2021, LLC Science and Innovations, Saratov, Russia

www.romj.org
Figure 2. Normalized cell index values of the control and tissue-engineered matrix groups. The point of maximum cell adhesion after seeding them into the wells is assumed to represent the normalization point.

Figure 3. Cell culture doubling time vs. control and tissue-engineered matrix groups.
Platelet types depending on activation are as follows:
I. Disc-shaped platelets without deformation;
II. Large platelets with pseudopod-shaped protrusions;
III. Large irregularly shaped platelets with pseudopods; they tend to aggregate in conglomerates;
IV. Spreading platelets; their cytoplasm spreads and fills the spaces between pseudopods;
V. Dense granules of platelets; pseudopods cannot be found due to the proliferation of the cytoplasm.

Scanning electron microscopy (SEM) of PHBV/PCL matrices was performed after the contact with PRP.

Assessment of cytotoxicity of tissue-engineered matrix samples with drug coatings

The effect of test samples on cell vital activity was assessed via the cell index (CI), measured by the Agilent xCELLigence RTCA DP system (ACEA Biosciences, USA). CI was calculated automatically by the device according to the formula: (Rn-Rb)/t, where Rb is the initial resistance value in the well containing the culture medium without cells, Rn is the resistance value at any time t in the well containing the cells. The cells were seeded at the density of 20,000 cells per well into an E-Plate 16 (ACEA Biosciences, USA). E-Plate Inserts (ACEA Biosciences, USA) were placed inside the plate wells with the matrix samples. The procedure was repeated at least 2 times for each sample. The wells, containing only cells, were used as a control. The wells filled with culture medium were used as the baseline resistance values.

Cells were incubated in standard DMEM/F12 medium supplemented with HAT, antibiotics/antimycotics in a CO₂ incubator at 37 °C and 5% CO₂.

CI was recorded as follows: every 15 min over the first 2 hours after cell seeding; every 30 sec within 2 hours after the introduction of the tested samples; then, every 15 min until the end of the experiment. The total time of the experiment was 74 hours. The cell index and the cell culture doubling time were calculated on the device automatically, and the data were presented as M±SD.

Statistical analysis

The obtained data were processed using the GraphPad Prism 7.0 Software (GraphPad, USA). The sample distribution was evaluated using the Kolmogorov–Smirnov test. The results are presented as medians and interquartile ranges (Me; Q1-Q3). Statistically significant differences between two independent groups were assessed via the Mann-Whitney U test. At p<0.05, the differences were considered statistically significant.

Results

Hemocompatibility of modified polymer matrix

We used the matrices presented in Table 1 to analyze the hemocompatibility of grafts.

Hemolysis

Hemolysis values did not exceed the norm of 2% (Table 2). There were no significant differences between the sample groups, with the exception of the surface of PHBV/PCL/A matrices, since the hemolysis there reached 100%.

Platelet aggregation

Polymerization of the matrix surface with PVP by ionizing radiation increased platelet aggregation by 1.2 times (Table 1). However, subsequent complexation between polymerized PVP, and iloprost and amphiphile, resulted in sevenfold reduction in platelet aggregation (p=0.012), compared with intact PRP (Table 2). Such significant decrease in platelet aggregation was apparently associated with iloprost action, since platelet aggregation on PHBV/PCL matrices with covalently cross-linked amphiphile alone did not lead to any aggregation reduction of comparable scale.

Platelet adhesion and platelet deformation index

PHBV/PCL matrices polymerized with PVP, demonstrated twofold increase in the platelet adhesion degree (p=0.0087) (Table 3, Figure 1), with a slight increase in the number of type IV platelets. Simultaneously, PDI after polymerization with PVP did not change much. The anti-thrombogenic and antimicrobial Ilo/A coating of PHBV/PCL/PVP matrices induced a 1.5-fold decrease (p=0.0007) in the number of adhered platelets, along with a twofold decrease in the number of type III platelets. Therefore, type I and II platelets became the prevalent types on the surface of the PHBV/PCL/PVP/Ilo/A matrices, ultimately causing a 1.5-fold reduction of PDI value (p=0.0006).

PHBV/PCL matrices with covalently cross-linked amphiphile exhibited a negative effect on platelet adhesion indicators. It was not possible to count the platelets and calculate the deformation index after the contact of PHBV/PCL/A matrices with PRP, due to the presence of a monolayer of platelets and plasma proteins on the surface of these matrices.

Cytotoxicity of polymer matrices with drug coatings

The results of hemocompatibility analysis accentuated the need to evaluate the effect of iloprost and amphiphile on growth and proliferation of cells. For this purpose, additional groups of polymer matrices with various compositions were manufactured for comparative assessment of cytotoxicity with the Ea.hy 926 control group (Table 4). Iloprost and cationic amphiphile were used either in combination or separately, making it possible to assess the cytotoxicity of each medicamentous coating individually.

The results of evaluating an impact of the studied samples on cell vital activity yielded the standard cell culture growth curve in control wells (Ea.hy 926). At the early stages of cultivation, the cell growth index was comparable to the control group in the experimental wells containing inserts of different polymer matrices. However, after the first day of cultivation, a decline in the slope of the curve was noted, indicating a slight decrease in the rate of cell growth and proliferation (Figure 2).

However, we did not observe the cytotoxic effect in any matrices – either unmodified, or modified by polymerization between PVP, and iloprost and/or cationic amphiphile.

PHBV/PCL/A matrices, modified by covalent crosslinking, significantly differed from other groups. In this group, on the first day of cell cultivation on PHBV/PCL/A matrices, a significant
reduction in the growth rate of the cell culture was noted. Subsequently, cell deaths and a sharp drop in the cell index value were noted by the end of the study.

This trend was confirmed by the analysis of the cell culture doubling time (Figure 3). The lowest value was observed in the Ea.hy 926 control group: 31.589±0.5648 hrs. Most experimental samples were characterized by a slightly higher value of doubling time, ranging from 36.1129±0.8352 hrs. (PHBV/PCL/PVP/A) to 46.6378±1.1842 hrs. (PHBV/PCL/PVP/IIo). The negative value of cell culture doubling time (-10.0602±0.8438 hrs.), signifying the death of the entire cell culture, was noted in the PHBV/PCL/A group, modified with covalent crosslinking.

Discussion

The bioabsorbable vascular graft with prolonged reabsorption, the polymers of which can be replaced by the patient’s own cells and tissues, subsequently forming a new vessel in its place, may serve an excellent replacement for the autologous arteries and veins [1, 19]. However, highly porous wall of such grafts induces thrombus formation and infection after the implantation [20]. Therefore, an antimicrobial and anti-thrombogenic coating applied to the graft surface should be capable of preventing such complications.

The polymerization of PHBV/PCL matrices performed in our study with PVP by an ionizing radiation at a dosage of 15 K Gy made it possible to develop a hydrogel substrate for the medicines, and to fill the pores of a vascular graft, thereby reducing the risk of thrombus formation, and simultaneously sterilizing the samples by radiation. However, our results implied that this procedure led to twofold increase in platelet aggregation and platelet adhesion degree, without increasing PDI and hemolysis values. Further complication of iloprost and cationic amphiphile helps eliminating the negative effect of PVP crosslinking, reducing the degree of platelets aggregation and adhesion to the baseline values. Modification of the surface by covalently cross-linked amphiphile resulted in 100% hemolysis, along with immense platelet aggregation and adhesion, making it impossible to estimate the platelet count. The negative effect of the covalent crosslinking technique has been confirmed by the cytotoxicity analysis of these matrices. At the same time, iloprost and cationic amphiphile were not cytotoxic. Furthermore, cell culture death can be explained by the presence of organic matter residues left after the covalent crosslinking.

Conclusion

Hence, we have demonstrated that iloprost and/or amphiphile coating improve hemocompatibility of polymer grafts without showing any cytotoxic effects. However, cytotoxicity per se could be neutralized by utilizing the complexation technique. The cytotoxicity analysis has revealed that organic substances used in the amphiphile covalent crosslinking usually had negative effects. In conclusion, complexation with polyvinylpyrrolidone as a binding agent can be considered the most suitable procedure for modifying the surfaces of small-diameter bioabsorbable vascular grafts.

Conflict of interest

The authors declare no conflicts of interest.

Acknowledgments

This study was funded by the Russian Science Foundation (grant No. 20-15-00075, “Development of a Small-Diameter Biodegradable Tissue-Engineered Vascular Graft with Anti-Thrombogenic and Antimicrobial Coating”).

Ethical approval

This article does not contain any materials associated with the studies, performed by any of its authors, that involved human participants or animals.

References

1. Taggart DP. Current status of arterial grafts for coronary artery bypass grafting. *Ann Cardiothorac Surg* 2013; 2(4): 427-430. https://doi.org/10.3978/j.issn.2225-319x.2013.07.21.
2. Pelletier-Galarneau M, Juneau D. Vascular graft infection: Improving diagnosis with functional imaging. *J Nucl Cardiol* 2020. https://doi.org/10.1007/s12350-020-02269-z.
3. Altun G, Pulathan Z, Hemsini D. Obturator bypass in the treatment of prosthetic graft infection: Classic but still effective. *Turk Gogus Kapi Damar Cerahisi* 2019; 26(3): 480-483. https://doi.org/10.5606/pgkdergusi.2018.15744.
4. Gentili A, Di Pumpo M, La Milia DI, Vallone D, Vangi G, Corbo MI et al. A six-year point prevalence survey of healthcare-associated infections in an Italian teaching acute care hospital. Int J Environ Res Public Health 2020; 17(21): 7724. https://doi.org/10.3390/ijerph17217724.
5. Welborn MB, Valentine RJ. Vascular infection. In: Creager MA, Dzau VJ, Llosalco J, Eds. Vascular Medicine: A companion to Braunwald’s heart disease Elsevier, Inc.; 2006: 859–879. https://doi.org/10.1016/j.8798-0721-0284-4.50067-1.
6. Sousa JV, Antunes L, Mendes C, Marinho A, Gonzalves A, Gonzalves Ó, et al. Prosthetic vascular graft infections: A center experience. *Angiol Cir Vasc* 2014; 10(2): 52-57. https://doi.org/10.4016/15164-706X(14)100050-3.
7. Asham S, Darouiche RO. Role of antibiotic-antimicrobial agents in controlling device-related infections. *Int J Artif Organs* 2011; 34(9): 752-758. https://doi.org/10.5301/iao.5000024.
8. Ulloa ER, Singh KV, Geriak M, Haddad F, Murray BE, Nizet V, et al. Cefazolin and ertapenem salvage therapy rapidly clears persistent *Staphylococcus aureus* bacteremia. *Clin Infect Dis* 2020; 71(6): 1413-1418. https://doi.org/10.1093/cid/ciz995.
9. Stanecvicute E, Na’amnih W, Kavaliauskas P, Prakapaite R, Ridziauskas M, Kevlicius L, et al. Delayed wound healing in diabetic (db/db) mice with *Pseudomonas aeruginosa* infection. *Wound Repair Regen* 2014; 22(9): 1430. https://doi.org/10.3390/microb17217724.
10. Zhao G, Hochwall PC, Usui ML, Underwood RA, Singh PK, James GA, et al. Delayed wound healing in diabetic (db/db) mice with *Pseudomonas aeruginosa* biofilm challenge: A model for the study of chronic wounds. *Wound Repair Regen* 2010; 18(5): 467-477. https://doi.org/10.1111/j.1524-475xs.2010.00608.x.
11. Ng VW, Chan JM, Sardon H, Ono RJ, García JM, Yang YY, et al. Antimicrobial hydrogels: A new weapon in the arsenal against multidrug-resistant infections. *Adv Drug Deliv Rev* 2014; 78: 46-62. https://doi.org/10.1016/j.addr.2014.10.028.
12. Ghosh C, Haldar J. Membrane-activated small molecules: Designs inspired by antimicrobial peptides. *ChemMedChem* 2015; 10(10): 1606-1624. https://doi.org/10.1002/cmdc.201500299.
13. Molchanova N, Hansen PR, Franzky H. Advances in Development of antimicrobial peptidomimetics as potential drugs. *Molecules* 2017; 22(9): 1430. https://doi.org/10.3390/molecules22091430.
14. Antonova LV, Sevostyanova VV, Rezova MA, Krivkina EO, Kudryavtseva YA, Barbarash OL, et al. Technology of Producing Functionally Active Biodegradable Small-Diameter Vascular Prostheses.
with Drug Coating. Patent No. 2702239. Registration date: October 07, 2019. Bull. No. 28. Russian. https://www.elibrary.ru/item.asp?id=41276645.

15. Ye X, Wang Z, Zhang X, Zhou M, Cai L. Hemocompatibility research on the micro-structure surface of a bionic heart valve. Biomed Mater Eng 2014; 24(6): 2361-2369. https://doi.org/10.3233/bme-141049.

16. Shen X, Su F, Dong J, Fan Z, Duan Y, Li S. In vitro biocompatibility evaluation of bioresorbable copolymers prepared from L-lactide, 1, 3-trimethylene carbonate, and glycolide for cardiovascular applications. J Biomater Sci Polym Ed 2015; 26(8): 497-514. https://doi.org/10.1080/09205063.2015.1030992.

17. Antonova LV, Krivkina EO, Rezvova MA, Sevostyanova VV, Tkachenko VO, Glushkova TV, et al. Technology for anti-thrombogenic drug coating of small-diameter biodegradable vascular prostheses. Sovrem Tekhnologii Med 2020; 12(6): 6-12. https://doi.org/10.17691/stm2020.12.6.01.

18. Jung F, Braune S, Lendlein A. Haemocompatibility testing of biomaterials using human platelets. Clin Hemorheol Microcirc 2013; 53(1-2): 97-115. https://doi.org/10.3233/ch-2012-1579.

19. Ren X, Feng Y, Guo J, Wang H, Li Q, Yang J, et al. Surface modification and endothelialization of biomaterials as potential scaffolds for vascular tissue engineering applications. Chem Soc Rev 2015; 44(15): 5680-574. https://doi.org/10.1039/c4cs00483c.

20. Antonova LV, Mironov AV, Yuzhalin AE, Krivkina EO, Shabaev AR, Rezova MA, et al. A brief report on an implantation of small-caliber biodegradable vascular grafts in a carotid artery of the sheep. Pharmaceuticals (Basel) 2020; 13(5): 101. https://doi.org/10.3390/ph13050101.

Authors:
Eugenia O. Krivkina – Junior Researcher, Laboratory of Cellular Technology, Department of Experimental Medicine, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. https://orcid.org/0000-0002-2500-2147.

Elena A. Velikanova – PhD, Researcher, Laboratory of Cellular Technology, Department of Experimental Medicine, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. https://orcid.org/0000-0002-1079-1956.

Eugenia A. Senokosova – PhD, Junior Researcher, Laboratory of Cellular Technology, Department of Experimental Medicine, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. https://orcid.org/0000-0002-9430-937X.

Maryam Yu. Khanova – Junior Researcher, Laboratory of Cellular Technology, Department of Experimental Medicine, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. https://orcid.org/0000-0002-8826-9244.

Tatiana V. Glushkova – PhD, Senior Researcher, Laboratory of Novel Biomaterials, Department of Experimental Medicine, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. https://orcid.org/0000-0003-4890-039.

Larisa V. Antonova – DSc, Head of the Laboratory of Cellular Technology, Department of Experimental Medicine, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. https://orcid.org/0000-0002-8874-0788.

Leonid S. Barbarash – DSc, Professor, Research Institute for Complex Issues of Cardiovascular Diseases, Academician of the Russian Academy of Sciences, Kemerovo, Russia. https://orcid.org/0000-0002-2814-4300.